Lothian NHS Board

Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN
Main Switchboard: 0131 242 1000

www.nhslothian.scot

Date 11/03/2026
Your Ref
Our Ref 11158

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – MIGRAINE PRESCRIBING

I write in response to your request for information in relation to migraine prescribing.

Question:

a. How many patients have been treated with the following drugs in the past 4 months:
   - Atogepant (Aquipta) – any disease
   - Erenumab (Aimovig) - any disease
   - Eptinezumab (Vyepti) – any disease
   - Fremanezumab (Ajovy) - any disease
   - Galcanezumab (Emgality) - any disease
   - Rimegepant (Vydura) – any disease
   - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Answer:

October 2025 - January 2026	
Medication	**Patient Count**
Atogepant	5<
Eptinezumab	0
Erenumab	123
Fremanezumab	71
Galcanezumab	22
Rimegepant	Informaiton Unavailable
Botulinum Toxin (Migraine Only)	237

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

b. How many patients have you treated in the last 4 months for acute migraine with:
    - Rimegepant (Vydura)

Answer:

This information is not held in a centrally extractable format. We are unable to distinguish between the indications of acute migraine or prophylaxis of episodic migraine.

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

c. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Answer:

Yes, we do actively initiate a treatment pause of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment but after a treatment period of 24months.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, \you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI/Pages/default.aspx

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive